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1. Summary 
Pneumococcal infections cause a large global health burden and the search for 
serotype-independent vaccines continues. Existing conjugate vaccines reduce 
nasopharyngeal colonisation by target serotypes. Such mucosal effects of novel 
antigens may likewise be important. CD4+ Th17 cell-dependent, antibody-
independent reductions in colonisation and enhanced clearance have been 
described in mice. Here we describe the evaluation of Th17 cytokine responses 
to candidate pneumococcal protein vaccine antigens in human cell culture, using 
adenoidal and peripheral blood mononuclear cells. Optimal detection of IL-17A 
was at day 7, and of IL-22 at day 11, in these primary cell cultures. Removal of 
CD45RO+ memory T cells abolished these responses. Age-associated increases 
in magnitude of responses were evident for IL-17A, but not IL-22 in adenoidal 
cells. There was a strong correlation between individual IL-17A and IL-22 
responses after pneumococcal antigen stimulation (p<0.015). Intra-cellular 
cytokine staining following PMA/Ionomycin stimulation demonstrated that >30% 
CD4+ T cells positive for IL-22 express the innate markers γδT-cell receptor 
and/or CD56, with much lower proportions for IL-17A+ cells (p<0.001). 
Responses to several vaccine candidate antigens were observed but were 
consistently absent, particularly in blood, to PhtD (p<0.0001), an antigen recently 
shown not to impact colonisation in a clinical trial of a PhtD-containing conjugate 
vaccine in infants. The data presented, and approach discussed have the 
potential to assist in the identification of novel vaccine antigens aimed at reducing 
pneumococcal carriage and transmission thus improving the design of empirical 
clinical trials. 
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2. Introduction 
Streptococcus pneumoniae (pneumococcus) remains a significant global cause 
of morbidity and mortality from diseases including pneumonia, meningitis, sepsis 
and otitis media, and is a particular challenge in developing countries. 
Pneumococcus accounts for 11% of all deaths in children under 5 years of age 
resulting in up to a million childhood deaths every year (1, 2). Of growing global 
concern are the emergence of non-vaccine serotypes, and antibiotic-resistant 
strains of pneumococcus (3, 4). 
 
Pneumococcus is a commensal of the human upper respiratory tract, with more 
than 90 capsular serotypes described. Asymptomatic colonisation of the 
nasopharynx with pneumococcus is more common in young children than in older 
children and adults (5-7). In contrast, the development of invasive pneumococcal 
disease is, relatively speaking, rare. Transmission between children and to other 
family members sustains the bacteria within a community (8). The introduction of 
multivalent pneumococcal conjugate vaccines (PCV) has resulted in overall 
decreases in the incidence of pneumococcal disease, but overall colonisation 
rates in children have changed little as non-vaccine serotypes replace formerly 
dominant vaccine types and also cause some replacement disease, limiting the 
overall efficacy of the vaccines in some settings (9-11). Thus, the development 
of serotype-independent pneumococcal vaccines is a priority in the fight against 
pneumococcus. 
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If, like PCVs, such vaccines are to impact disease by reducing carriage and 
transmission, understanding of naturally-acquired mucosal immune responses to 
pneumococcus and how they affect pneumococcal colonisation could guide 
antigen selection and vaccine formulation. Antibody-independent CD4+ T cell-
dependent reduction of pneumococcal colonisation has been demonstrated in 
mice (12-14). A role for CD4+ Th17 cells, which can kill and clear pneumococci 
by recruiting neutrophils to the site of infection, has been proposed (15, 16). Th17 
cells exist in adults and children (15), and produce both interleukin-17A (IL-17A) 
and interleukin-22 (IL-22) (17, 18). The stimulation of production of IL-17A and 
IL-22 by candidate pneumococcal vaccine antigens could indicate their capacity 
to influence pneumococcal colonisation either by preventing acquisition or 
promoting clearance.  
 
Here we describe the measurement and characteristics of Th17 responses in 
human primary cell cultures from blood and adenoidal tissue (nasal associated 
lymphoid tissue) of children, and the use of this technique to screen potential 
pneumococcal vaccine candidate antigens. In particular, we show that for an 
antigen that recently failed to reduce carriage in a clinical trial, no demonstrable 
Th17 responses could be seen. 
 
3. Materials and methods 
3.1 Subjects and samples 
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With informed consent, adenoids were collected from children aged 1-14 years, 
who were undergoing routine adenoidectomy or adenotonsillectomy at the 
Bristol Royal Hospital for Children. Up to 10mL of anti-coagulated peripheral 
blood was additionally collected from some children. Children were healthy at 
the time of surgery.  Exclusion criteria were: recent/current antibiotics, known 
immunodeficiency or immunosuppressive treatment within 2 weeks of surgery. 
Clinical information is provided in detail in Supplementary table 1.  They had 
previously received 7 valent pneumococcal conjugate vaccine almost without 
exception, and it should be noted that the majority of children were aged 3 
years and above.  The total number of children studied was 75, and the 
numbers in the comparisons described varied between 3 and 38.   Amongst 
those from whom a nasal swab was obtained and analysis completed (n=61), 
the pneumococcal carriage rate by culture was 39%.  Ethical approvals were 
obtained as appropriate from the North Somerset and South Bristol and PATH 
Research Ethics Committees.   
 
3.2 Antigens   
The whole-cell killed unencapsulated pneumococcal antigen (WCA) was made 
as described in (19) at a concentration of killed bacteria representing 1x106cfu/ml, 
as determined in previous experiments (data not shown).  Different WCA 
preparations have been shown to be similar with respect to specific antigen 
content, and induction of immunological responses in laboratory animals.  
Recombinant proteins Choline binding protein A (CbpA), Pneumococcal surface 
antigen A (PsaA) and Pneumococcal surface protein A (PspA) were purified from 
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recombinant  E.coli  expressing the respective cloned genes (20, 21).  
Recombinant CbpA, PsaA and PspA were assessed to be >95% pure by SDS-
PAGE and Coomassie brilliant blue staining.  Recombinant protein 
Pneumococcal histidine triad protein D (PhtD) was produced as previously 
described (22), and isothermal calorimetry was performed to confirm  zinc  
binding with ID NMR to show associated changes in protein structure. All proteins 
were used at a concentration of 8µg/ml to stimulate optimal CD4+ T cell 
proliferation as determined in previous experiments, as shown in supplementary 
figure 1.  The duration of cell stimulation varied between experiments and is 
shown in the respective figure legends. 
 
3.3 Cell isolation and culture 
Adenoidal tissue was collected into Hanks' Balanced Salt Solution (HBSS)/ 2% 
Hepes (Thermo Scientific/Life Technologies, USA and Sigma-Aldrich Company 
Ltd., UK) with 10% Penicillin/Streptomycin (Sigma-Aldrich Company Ltd., UK), 
and processed fresh within 24 hours. Peripheral blood was processed within 6 
hours of collection and was prepared by diluting it 1:1 with HBSS/2% Hepes. 
Mononuclear cells from adenoids and peripheral blood were separated on Ficoll-
density gradients as previously described (23). Cells were cultured in 48-well 
culture plates at 1x106 cells/ml in a 1 mL volume, in either complete  Roswell Park 
Memorial Institute Medium 1640 (RPMI) (Themo Scientific/Life Technologies, 
USA) containing 20mM Hepes, 2mM L-Glutamine, 1% Penicillin/Streptomycin 
(Sigma-Aldrich Company Ltd., UK)  with 10% Foetal bovine serum (Sigma-Aldrich 
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Company Ltd., UK) for cytokine analysis, or in complete RPMI media/2% human 
serum (Sigma-Aldrich Company Ltd., UK) for intra-cellular cytokine analysis.   
 
3.4 Cell depletions 
Memory T cells (CD45RO+) were depleted from the mononuclear cell population 
using positive selection magnetic-activated cell sorting (MACS) according to the 
manufacturer’s guidelines (Miltenyi Biotech, Germany). A positive control (“add 
back”) was made by mixing the depleted cells with the positively selected cells 
retained on the magnet during the cell separation procedure. The purity of these 
cell suspensions (CD45RO- and CD45RO+) was confirmed by 
immunofluorescence staining (CD4-APC, CD45RO-FITC and CD45RA-PE-Cy7 
(BD Biosciences, UK)) and flow cytometry using a FACS Canto II (BD 
Biosciences, UK), analysed with FlowJo software (FlowJo, LLC, USA) analysis 
was conducted by gating on lymphocyte cells identified by their forward/side 
scatter profile, gating the CD4+ population and finally gating on CD45RO and 
CD45RA cell populations.  CD45RO and CD45RA cells were re-mixed at a 1:1 
ratio (proportion of CD45RO cells before depletion was 16-38%, and <1% after 
depletion).  
 
3.5 IL-17A and IL-22 immunoassays 
Cells were incubated with or without antigen, and IL-17A and IL-22 was measured 
in the cell supernatant collected between 1-15 days using a Human IL-17A or an 
IL-22 ELISA Ready-Set-Go kit according to the manufacturer’s instructions 
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(Affymetrix eBiosciences,USA).  In most cases the same cell supernatant was 
used for both cytokine assays, except for the experiments shown in figures one 
and two. Supernatants were stored at -20oC for short term and at -80oC for long 
term storage. 
  
3.6 Intra-cellular cytokine production 
Intra-cellular cytokine staining was conducted on day 7 of cell culture with or 
without antigen stimulation. Cells were re-stimulated with antigen on day 6 to 
boost their cell specific cytokine responses. On day 7 PMA 0.05 µg/ml, Ionomycin 
1 µg/ml (Sigma-Aldrich Company Ltd., UK) and Golgistop (BD Biosciences, UK) 
were added for 5 hours. Cell viability staining, cell surface staining and the 
intracellular cytokine staining processes were carried out using a BD 
Cytofix/Cytoperm Fixation/Permeabilization Kit according to the manufacturer’s 
instructions (BD Biosciences, UK). Fixable viability dye eFluor780 (Affymetrix 
eBiosceinces,USA) was used to assess cell viability. Cell surface antibody 
markers CD4 Alexa Fluor700 (BD Biosciences, UK), CD56 PE-Cy7/ Brilliant 
Violet 510 (BD Biosciences, UK/ Biolegend, USA), TCR yδ FITC/ PE-Cy5.5 (BD 
Biosciences, UK/ Beckman Coulter, USA) and intracellular antibodies IL-17A PE/ 
Brilliant Violet 605 (Affymetrix eBiosceinces,USA/ Biolegend, USA) and IL-22 
eFluor660 (Affymetrix eBiosceinces,USA) were used and concentrations had 
been pre-determined by titrations. The fixed and stained cells were left overnight 
at 4oC to reduce autofluorescence before being analysed on a LSR II flow 
cytometer (BD Biosciences, UK), where 20,000 live cells in the lymphocyte gate 
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were collected per stimulation. Analysis was carried out using the software 
program FlowJo, and only live cells in the lymphocyte gate were analysed.  
Analysis was conducted by gating on lymphocyte cells identified by their 
forward/side scatter profile, live cells were gated based on the live/dead cell 
marker, then either IL-17A+ or IL-22+ populations were identified, followed by the 
CD4+ population and finally the CD56+ or γδTCR+ cell populations were gated 
on. 
 
3.7 Statistical analysis 
 
Significance of differences between groups was analysed using a paired t-test. 
The relationships between age and cytokine responses was compared using 
linear regression analysis. Pearson correlation was used to investigate 
correlation in an individual’s IL-17A and IL-22 cytokine response to an antigen. 
Group mean cytokine responses to the panel of antigens were compared by 
repeated measures one-way ANOVA. Statistical analysis was performed using 
GraphPad Prism version 6 (GraphPad Software, USA). 
 
4. Results 
 
Optimisation of assay system and identification of responding cells  
In order to determine optimal methodology for detecting responses, time course 
experiments were initially conducted using peripheral blood mononuclear cells 
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(PBMC), and adenoidal mononuclear cells (AMNC) stimulated with WCA. The 
Th17 cytokines IL-17A (Figure 1a) and IL-22 (Figure 1b) responses, when 
present, were consistently strong at days 7 and 11 respectively and these timings 
were used in subsequent experiments. 
To identify the phenotype of responding cells, two experiments showed that 
depletion of memory T cells (CD45RO+) from PBMC almost entirely eliminated 
detectable IL-17A responses (Figure 2.a), which were restored by their 
replacement (Figure 2.b). This finding was confirmed in four additional children 
whose undepleted PBMC IL-17A responses were median (range) 40.5 (6.3-65.6) 
pg/ml on day 5, and CD45RO-depleted (99% purity in all) IL-17A responses 0 (0-
0.4) pg/ml (data not shown). 
 
Characterisation of cytokine responses 
Experiments were performed to establish the key characteristics of these 
responses.  There was a correlation between age and the IL-17A responses to 
WCA in AMNC, but little evidence that age influenced the IL-22 response in 
AMNC or the IL-17A or IL-22 response in PBMC. (Figure 3). There was a strong 
positive correlation in the magnitude of IL-17A and IL-22 responses to WCA and 
CbpA in individual subjects in both PBMC and AMNC (Figure 4).   
Intracellular cytokine staining was used to investigate further the phenotype of 
cells producing IL-17A and IL-22.  For intracellular cytokine staining, IL-22 
detection was measured after 7 days rather than the optimal day 11 (Figure 5), 
as there were limited available cells. Live lymphocyte gating (based on forward 
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and side scatter parameters) in flow cytometric staining for intracellular IL-17A 
and IL-22 showed strong evidence of increases of 2% or more above the 
background following stimulation with the recombinant pneumococcal antigen 
CbpA (p=0.0021, paired t test) (Figure 5.a). 
Fifty percent or more IL-17A+ live lymphocytes were CD4 positive, with a 
somewhat lower percentage of IL-22+ AMNC expressing CD4 (Figure 5. b). 
Following stimulation with WCA there was strong evidence of an expansion in the 
CD4+ IL-17A+ AMNC expressing compared to cultured cells that were stimulated 
with only PMA/Ionomycin. 
There was very strong evidence that a much higher proportion of IL-22+ CD4+ 
AMNC expressed one, the other or both of the innate cellular markers CD56 and 
TCR-γδ, than IL-17A+ CD4+ AMNC both before and after antigen stimulation 
(Figure 6). 
 
IL-17A and IL-22 responses to a panel of pneumococcal antigens 
In order to compare responses to different candidate vaccine antigens, cytokine 
release by PBMC and AMNC following stimulation with pneumococcal antigens, 
including 3 additional proteins previously investigated as candidate vaccines, 
were measured. Results showed significant variation between antigens (Figure 
7), and in particular there was little apparent response to the surface protein PhtD 
in PBMC, while responses to the additional proteins PsaA and PspA were weak 
in AMNC. 
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Additional post-hoc analysis, added during the peer review process 
(supplementary figures 3 and 4), indicated apparent significant differences 
between WCA and the recombinant proteins tested, apart from between WCA 
and CbpA in adenoids and differences between PhtD and PspA and PsaA in 
blood but not clearly in adenoids. 
 
5. Discussion 
We have defined IL-17A and IL-22 responses to pneumococcal antigens in 
adenoidal and peripheral blood mononuclear cells, and thus propose a tool with 
which to evaluate Th17 cellular immune responses to candidate pneumococcal 
vaccine antigens. This may assist prioritization for assessment of their effects on 
colonisation and their potential prevention of transmission. 
 
Previous Th17 experiments in mice found day 3 to be optimal to detect IL-17A 
responses, and IL-17A can also be detected from human pharyngeal tonsil 
mononuclear cells after 3 days (15). However, we have previously shown that 
CD4+ T cell proliferation in response to pneumococcal antigens in children is 
optimal after 7 days of stimulation in culture (24) and likewise in the experiments 
presented here, 7 days of culture was optimal for IL-17A detection while 11 days 
was the best for IL-22 detection (Figure 1). We have previously demonstrated 
clearer and more reliable mucosal responses in adenoidal than tonsillar cells (25). 
Although these relatively slow response rises might suggest that these are not 
memory responses following previous exposure, depletion of CD45RO+ cells 
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resulted in their almost complete disappearance (Figure 2), confirming that they 
are anamnestic, albeit not extremely rapid, in concordance with previous studies 
of other aspects of these mucosal cellular immune responses (24). 
 
Both rates of colonisation and invasive disease due to pneumococcus drops 
rapidly with increasing age in young children (5-7), suggesting progressive rises 
in specific immunity either in response to exposure, or through immune 
maturation or both. Both we (5) and others have shown evidence of emergence 
of specific B cell immunity to pneumococcal antigens particularly during the 
second year of life (7, 26). IL-17A responses to pneumococcal antigens in blood 
leukocytes are higher in adults than children and vary between children in 
different populations, which is likely to reflect different levels of exposure to 
pneumococcus (15, 27). In the results presented here, there was little evidence 
of increasing Th17 responses with age, apart from rises in adenoidal cellular 
elaboration of IL-17A in response to pneumococcal stimulation (Figure 3). The 
IL-22 responses of individual children in blood and adenoids are not significantly 
correlated to each other, but IL-17A responses are (supplementary figure 2), 
and close inspection of the data (figure 3b) suggests that the reason the IL-17A 
age effect is not seen in blood lymphocytes is the more consistently detectable 
responses in the younger children studied.   It is also possible that clearer age-
dependency was not seen in this study in the context of wide variation between 
individuals owing to other potentially confounding factors including timing of 
recent exposure and colonisation.  As noted, previous studies by our group in 
this paediatric population showed a consistent steep rise in antibodies to a 
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range of pneumococcal antigens during the second year of life (5), suggesting 
that few if any of the children reported here are likely never to have been 
colonised or that serology done in this group would be likely to predict or explain 
the differences we observed.  Alternatively, or in addition, much of any cytokine 
increase may occur by the end of the second year of life as seen for antibodies 
to pneumococcal antigens (5), while the children studied here were nearly all 
aged 2 years or older. 
 
The classic Th17 pathway shows production of IL-17A and IL-22 to be from CD4+ 
T cells under the influence of TGF-β, IL-6 and IL-23 (15, 28-30). Mucosal 
immunity to colonisation by pneumococcus can be antibody independent and 
CD4+ T cell-dependent in mice (14, 15), and CD4+ T cells may be important in 
protection of humans against pneumococcal colonisation and disease. For 
example in HIV-infected individuals with reduced numbers of CD4+ T cells and 
high risk of this infection (31). The question then arises whether CD4+ T cells are 
an important cellular source of IL-17A and IL-22. While it was clear that both 
cytokines were elaborated by cells falling within the lymphocyte scatter gate, our 
results suggest that CD4+ T cells are a source of IL-17A following stimulation with 
pneumococcal antigens, but this was not clearly demonstrated for IL-22 under 
the conditions we used (Figure 5). Nevertheless, we did show evidence of strong 
correlation at an individual level between the size of IL-17A and IL-22 responses 
measured after pneumococcal antigen stimulation both in AMNC and PBMC 
(Figure 4). Further characterisation of CD4+ T cells expressing the two cytokines 
both before and after pneumococcal antigen stimulation showed that those 
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producing IL-22 were much more likely to be expressing innate cell phenotypes 
(Figure 6).  Both innate NK T cells (32, 33) and TCR- Ƴδ cells (34, 35) have 
previously been shown to be sources of IL-17A and IL-22, and both these cell 
types have been shown to recruit neutrophils to the pneumococcal infection site 
(36, 37). Our results extend these observations to include CD4+ T cells 
expressing innate markers as a potential source of IL-22, particularly in the 
human upper respiratory tract.  In this context it would be of interest to conduct 
further CD45RO depletion experiments to examine the effect on IL-22 production. 
 
We and others have previously investigated mucosal and systemic B cell and T 
cell CD4+ responses to several pneumococcal antigens including WCA, CbpA, 
PsaA and PspA (5, 12, 23, 24, 38). These antigens have also been shown to 
have protective effects in murine models of pneumococcal colonisation and 
infection (39-41). There has been strong interest in PhtD as a vaccine candidate 
antigen (22). The IL-17A and IL-22 responses we demonstrate here to these 
antigens in primary human cell cultures, notwithstanding wide inter-individual 
variation, demonstrate significance differences between antigens as well (Figure 
7). The relatively larger responses seen in blood than adenoidal cells occur in the 
context of much lower background cytokine production by unstimulated cultures 
and a known lower T-regulatory environment and has previously been observed 
by us and others(42) (43), however further investigation is required to further 
understand this observed difference.   Of particular note were the relative lack of 
responses to PhtD evident in blood, an antigen which has recently been shown 
to lack efficacy against pneumococcal colonisation in children although when 
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injected parenterally with aluminium rather than a T-cell adjuvant (44). Although 
it has been proposed that this and related pneumococcal proteins, which are 
released extra-cellularly by the bacterium in large quantities, might act as a sink 
for potentially opsonophagocytosing antibodies (45), our data suggest PhtD may 
also fail to induce cellular immune responses.   
 
We here describe Th17 responses to pneumococcal antigens in human cell 
cultures in detail. This approach not only allows detailed description of the 
immunological responses to pneumococcus in the upper respiratory tract of 
children, but also has potential to guide antigen selection for candidate vaccines 
aiming to impact upon carriage and transmission. Future studies should seek to 
elucidate whether such responses reliably predict protection against acquisition 
or clearance of carriage in children having repeated evaluation of colonisation 
over time. 
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Figures and figure legends 
 
 
 
Figure 1.  Detection of Th17 cytokines (a) IL-17A and (b) IL-22 in three children’s 
PBMC, and in one child’s AMNC after WCA stimulation over a 15 day time course. 
Each data point represents a child’s cytokine response with the background 
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signal subtracted. Each supernatant was taken from a different well of cells at 
each time point.  The PBMC IL-17A response for child 3 was anomalous at days 
9 and 11, however the response at day 7 fitted the broader trend. 
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Figure 2. IL-17A responses to WCA over 9 days (a) in undepleted PBMC and 
memory T cell-depleted (CD45RO-) PBMC, and (b) in memory T cell-depleted 
PBMC with the memory T cells added back. CD45RO-depleted cells were 
99.93% and 99.78% pure (data not shown). For child 1 the add back experiment 
was only conducted between days 5 and 9 due to limited cells numbers. At each 
time point supernatants from different wells were used and values are shown with 
unstimulated cells signals subtracted. 
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Figure 3. The association between age and IL-17A and IL-22 responses (above 
background) to WCA in (a) PBMC and (b) AMNC. Each data point represents a 
child’s IL-17A or IL-22 response at day 7 or 11 respectively to WCA, supernatants 
at both time points were collected from the same well of cells.   n = 37-39. Linear 
regression lines are shown with corresponding r2 and p values. 
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Figure 4.  Individual day 11 IL-22 responses to WCA (left) and CbpA (right) 
plotted against corresponding day 7 IL-17 responses in (a) PBMC and (b) AMNC. 
Values are shown with unstimulated background values subtracted, supernatants 
at both time points were collected from the same well of cells.  n=26-38. 
Pearson’s correlation coefficients and two-tailed t test p values are shown. 
 
 
 
 
 28 
 
 
Figure 5. Intracellular cytokine staining analysis to identify IL-17A+ and IL-22+ 
expressing AMNC in response to WCA and CbpA at day 7 and to determine their 
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CD4+ expression level. (a)  The percentage of live lymphocytes producing IL-17A 
or IL-22.  The average percentage of live cells in the lymphocyte gate was 59.5%, 
n=14 (data not shown). (b) Comparison of the percentage of cytokine producing 
live lymphocytes expressing CD4+ in response to WCA and CbpA. Statistical 
analysis was conducted using a paired t-test with the p values shown. 
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Figure 6. Expression of innate cellular markers on CD4+ IL-17A+ and IL-22+ 
AMNC at day 7. Each bar represents the mean percentage of live CD4+ cytokine 
producing cells expressing combinations of the cell surface markers CD56 and 
TCR-γδ in response to WCA and to CbpA.  n=14.  Paired t-test was used to 
compare the IL-17A+ cells expressing combinations of the innate cellular 
markers, with live IL-22+ cells expressing combinations of the innate cellular 
markers,.  The p values shown relate to the proportions of cells expressing either 
combination of markers (CD56 or γδTCR or both).  Standard deviations for the 
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combined innate marker percentages for the six bars are, respectively 15.5; 12.3; 
11.9; 21.1; 22.1; 21.3. There are no significant differences between conditions. 
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Figure 7.  IL-17A and IL-22 responses to WCA and to a panel of pneumococcal 
antigens – CbpA, PsaA, PspA and PhtD - in (a) PBMC and (b) AMNC.  Each data 
point represents a child’s IL-17A or IL-22 response at day 7 or 11 respectively.  
All PBMC or AMNC samples were tested for all antigens.  The background is 
shown (media) for reference, however the background has been subtracted from 
the data points showing the responses to each of the stimulations.  Supernatants 
at both time points were collected from the same well of cells.  PBMC n=16 and 
AMNC n=14.  The bar represents the mean. Comparing group means (excluding 
the media background) was conducted by one-way ANOVA with the p values 
shown. 
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Supplementary table 1.  Demographic data and history of chronic, recent 
illnesses and infections in the study population. 
 
Child Figure(s) 
data from 
child is 
used in 
Age 
(yrs) 
Gender 
(M=Male, 
F=Female) 
Chronic illnesses.  
Recent illnesses and infections 
1 2 3 F  
2 2, 3 1 F Asthma, Respiratory tract infection 
3 2,3 3 M Otitis media 
4 2 6 F  
5 2 4 M  
6 2 5 M  
7 1,3,4 4 F Asthma 
8 3,4 10 F Urinary retention, Tonsillitis 
9 1,3,4 5 M Tonsillitis 
10 1,3,4 5 F  
11 3,4 3 M Rhinitis, otitis media 
12 3,4,7 4 M Otitis media 
13 3,4,7 4 M Asthma, Tonsillitis 
14 3,4,7 2 M Asthma, Hay fever, Rhinitis 
15 3,4,7 6 F  
16 3,4,7 4 M Asthma 
17 3,4 14 F Tonsillitis 
18 3,4,7 5 F Asthma 
19 3,4,7 5 F Asthma, Otitis media, Tonsillitis 
20 3,4,7 4 M Otitis media 
21 3,4,7 4 M  
22 3,4,7 7 F Upper respiratory infection 
23 3,4 2 M Hypothyroidism, Otitis media 
24 3,4,7 4 M Otitis media, Tonsillitis 
25 3,4,7 11 F  
26 3,4 6 M Asthma, Tonsillitis 
27 3,4 8 M Asperger's Syndrome 
28 3,4 11 F Tonsillitis 
29 3,4 2 F  
30 3,4 2 M  
31 3,4 5 F Juvenile chronic arthritis, uveitis 
32 3,4 3 M  
33 3,4 5 M Tonsillitis 
34 3,4 4 M  
35 3,4 3 M Asthma, Tonsillitis 
36 3,4 5 F CHARGE Syndrome 
37 3,4,7 5 M Otitis media 
38 3,4,7 7 M  
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39 3,4,7 3 F  
40 3,4,7 10 F  
41 3,4,7 4 M Tonsillitis 
42 3,4,7 5 M  
43 3,4,7 2 M 
Cerebral palsy, chronic lung disease of 
prematurity, nasal obstruction, Pneumonia 
44 3,4,7 2 M Tonsillitis 
45 3,4,7 7 F Obstructive sleep apnoea 
46 3,4,7 3 M Asthma, tonsillitis, otitis media 
47 3,4,7 7 F Obstructive sleep apnoea 
48 3,4 5 F Obstructive sleep apnoea, varicella 
49 3,4,7 2 M 
Obstructive sleep apnoea, conductive 
deafness 
50 3,4 3 F Obstructive sleep apnoea, otitis media 
51 3,4 8 M Obstructive sleep apnoea 
52 3,4 3 M 
Tonsillitis, otitis media, respiratory tract 
infections, prematurity, chronic lung disease 
53 3,4 3 F Obstructive sleep apnoea, asthma, tonsillitis 
54 3,4 4 F Obstructive sleep apnoea 
55 3,4 10 F 
Obstructive sleep apnoea, respiratory tract 
infections 
56 3,4 8 M 
Obstructive sleep apnoea, tonsillitis, 
impetigo 
57 3,4 4 F Tonsillitis, otitis media 
58 5,6 1 F Obstructive sleep apnoea 
59 3,4 8 F 
Respiratory obstruction, otitis media, 
deafness 
60 3,4 2 F Obstructive sleep apnoea, otitis media 
61 5,6 3 F Respiratory obstruction 
62 5,6 4 M 
Obstructive sleep apnoea, previous 
pneumonia 
63 5,6 7 M 
Obstructive sleep apnoea, asthma, atopy, 
sickle trait 
64 3,4 2 M Obstructive sleep apnoea 
65 5,6 4 M Respiratory obstruction, deafness 
66 3,4 4 M Asthma, respiratory obstruction, varicella 
67 5,6 3 F Obstructive sleep apnoea 
68 5,6 5 F 
Obstructive sleep apnoea, tonsillitis, 
deafness, otitis media 
69 5,6 7 M Obstructive sleep apnoea, tonsillitis 
70 5,6 4 F Obstructive sleep apnoea 
71 5,6 4 M Obstructive sleep apnoea 
72 5,6 5 M Obstructive sleep apnoea, tonsillitis 
73 5,6 5 F Obstructive sleep apnoea, rhinitis 
74 5,6 2 F Respiratory obstruction, eczema 
75 5,6 3 M Obstructive sleep apnoea, tonsillitis, eczema 
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Footnotes 
- All subjects were reported to be fully immunised apart from child 43 who 
had had no vaccines. 
- Case report form was modified from subject 45 onwards to include 
indication for surgery - frequently obstructive apnoea. 
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Supplementary figure 1.  Human nasal associated lymphoid tissue optimal / 
sub-maximal CD4+ proliferation responses to (a) CbpA, (b) PsaA, (c) PspA and 
(d) PhtD at day 7.  The background unstimulated responses have been 
subtracted.  Bars represent the mean with the standard deviation shown. 
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Supplementary figure 2.  Individual PBMC and AMNC (a) IL-17A and (b) IL-22 
responses to WCA.  Data points represent a child’s IL-17A or IL-22 response at 
day 7 and 11 respectively.  The background unstimulated responses have been 
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subtracted.  Supernatants at both time points were collected from the same well 
of cells.   n=20.  Pearson’s correlation coefficients and two-tailed t test p values 
are shown. 
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Supplementary figure 3.  IL-17A and IL-22 responses to WCA and to a panel 
of pneumococcal antigens – CbpA, PsaA, PspA and PhtD - in (a) PBMC and (b) 
AMNC.  Each data point represents a child’s IL-17A or IL-22 response at day 7 
or 11 respectively.  All PBMC or AMNC samples were tested for all antigens.  
The background is shown (media) for reference, however the background has 
been subtracted from the data points showing the responses to each of the 
stimulations.  Supernatants at both time points were collected from the same 
well of cells.  PBMC n=16 and AMNC n=14.  The bar represents the mean.  
Wilcoxon rank sum test was conducted between WCA and each recombinant 
protein, p values shown. 
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Supplementary figure 4.  IL-17A and IL-22 responses to WCA and to a panel 
of pneumococcal antigens – CbpA, PsaA, PspA and PhtD - in (a) PBMC and (b) 
AMNC.  Each data point represents a child’s IL-17A or IL-22 response at day 7 
or 11 respectively.  All PBMC or AMNC samples were tested for all antigens.  
The background is shown (media) for reference, however the background has 
been subtracted from the data points showing the responses to each of the 
stimulations.  Supernatants at both time points were collected from the same 
well of cells.  PBMC n=16 and AMNC n=14.  The bar represents the mean.  
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Wilcoxon rank sum test was conducted between PhtD and PsaA or PspA, p 
values shown. 
 
 
